Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II trial of intra-arterial autologous bone marrow mononuclear cells for critical limb ischemia
2009-013636-20Phase 2Active
- Sponsor
- Andalusian Progress and Health Public Foundation
- Start
- Jan 2010
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of autologous bone marrow-derived mononuclear cell in chronic limb-threatening ischemia (CLTI) (4 arms), sponsored by Andalusian Progress and Health Public Foundation. Primary endpoint: Adverse events and serious adverse events. Started Jan 2010; status: active.
02
Drugs
autologous bone marrow-derived mononuclear cell
03
Conditions
chronic limb-threatening ischemia (CLTI)
Beyond the preview
Go deeper on 2009-013636-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-013636-20.